3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Glioma
9
Neuroblastoma
8
Breast Neoplasms
6
Neoplasms
5
Thyroid Cancer, Papillary
4
Sarcoma
4
Neurofibroma, Plexiform
4
Central Nervous System Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Thyroid Neoplasms
3
Pheochromocytoma
3
Paraganglioma
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Neurofibromatosis 1
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Diseases
2
Thoracic Neoplasms
2
Salivary Gland Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neuroendocrine Tumors
2
Neoplasms by Site
2
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Wilms Tumor
×
CNS
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA